Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379244 | 0.85 | MAPK1 (0.66) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL30252940 | 0.85 | MAPK1 (0.62) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL27993916 | 0.83 | MAPK1 (0.48) | MAPK1HPGDAHRNOTUMMAPT | |
| SCHEMBL19644152 | 0.81 | MAPK1 (0.61) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL19652058 | 0.81 | MAPK1 (0.69) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL6618480 | 0.80 | MAPK1 (0.56) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL3149403 | 0.79 | MAPK1 (0.62) | MAPK1HPGDAHRSIGMAR1L3MBTL1 | |
| SCHEMBL11882123 | 0.79 | TMPRSS2 (0.58) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL11966963 | 0.79 | MAPK1 (0.58) | MAPK1HPGDAHRDPP4NOTUM | |
| SCHEMBL537566 | 0.78 | MAPK1 (1.00) | MAPK1HPGDAHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| US-8343961-B2 | Substituted heterocyclic compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2264037-A1 | Vasopressin v1a antagonists | Vantia Limited (GB) | 2010-12-22 | — | — | EP | disclosed |
| US-20100249115-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | ARQULE, INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249115-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CYP11B2, GABBR1, CNR1 | MAPK1 2135/4885HPGD 223/4885AHR 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.